Nextbiotix Receives €7 Million for Development of Bacteria-based IBD Therapy
News
Nextbiotix has secured €7 million ($8.2 million) in funding to develop NBX1650, the company’s lead bacterial candidate for the treatment of inflammatory bowel disease (IBD). This first round of funding ... Read more